Jim Tananbaum is listed as a director on 9 SEC Form D filings by 6 issuers between Jul 2013 and Feb 2025. Largest by amount reported sold: Kinnate Biopharma Inc. (San Diego, CA — biotechnology — 2020; $98M reported sold to 24 investors), LifeMine Therapeutics, Inc. (Cambridge, MA — biotechnology — 2017; $70.1M reported sold to 10 investors), Latigo Biotherapeutics, Inc. (Thousand Oaks, CA — biotechnology — 2025; $50M reported sold to 7 investors), Mindstrong, Inc. (Palo Alto, CA — other technology — 2017–2018; $31M reported sold to 8 investors), Sequenta, Inc. (South San Francisco, CA — industry reported as "Other" — 2013; $20M reported sold to 14 investors) and 1 more (all listed below).
What this means A repeat sponsor — 6 separate companies raised money with this person listed as director, over about 12 years. Across those companies the filings report $279.1M sold in total.
Listed alongside Richard Klausner (4 shared filings), Nima Farzan (3 shared filings), Paul Dagum (3 shared filings), Carl L. Gordon (2 shared filings), Keith Flaherty (2 shared filings) and 30 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Jim. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, LA, ME, MO, MS, MT, NASAA, NC, NH, NM, OR, RI, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 9 public filings for Jim Tananbaum and found 9 differences, 1 worth asking the sponsor about: Jim Tananbaum is no longer listed on the Mar 29, 2019 amendment; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.